LXRP - Lexaria Bioscience Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2850
+0.0050 (+1.79%)
At close: 3:01PM EDT
Stock chart is not supported by your current browser
Previous Close0.2800
Open0.2998
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2700 - 0.2998
52 Week Range0.2300 - 1.3400
Volume40,073
Avg. Volume113,060
Market Cap23.005M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.77
  • GlobeNewswire

    Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing

    NEW YORK, March 30, 2020 -- Life Sciences Investor Forum today announced that the presentations from its inaugural conference are now available for on-demand viewing at.

  • GlobeNewswire

    Lexaria Bioscience Corp. to Webcast Live at Life Sciences Investor Forum March 26

    Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platform today announced that Chris Bunka, Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on March 26. Investigation into its patented DehydraTECH drug delivery technology will be pursued to determine the extent of improvements possible in antiviral drug delivery designed to fight against coronavirus disease COVID-19.

  • GlobeNewswire

    Virtual Conference for Life Sciences Companies and Investors Broadcast Live March 26, 2020

    NEW YORK, March 24, 2020 -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry.

  • ACCESSWIRE

    Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / March 23, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria's patented DehydraTECHTM drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories in North America and internationally as soon as possible. Within the Lexaria Pharmaceutical Corp. business unit resides Intellectual Property for enhanced delivery of drugs such as non-steroidal anti-inflammatories ("NSAIDs"), vitamins, hormone treatments utilizing estrogen or testosterone and phosphodiesterase ("PDE5") inhibitors; with expansion now underway to include antiviral drugs as well.

  • ACCESSWIRE

    Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

    KELOWNA, BC / ACCESSWIRE / March 19, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria's DehydraTECHTM drug delivery platform for enhancing delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19. Researchers around the world are currently investigating various antiretroviral drugs as potential candidates to combat COVID-19.

  • ACCESSWIRE

    Lexaria Provides Update on Two Licensed Clients

    KELOWNA, British Columbia / ACCESSWIRE / March 4, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has successfully processed its first DehydraTECHTM-enabled liquid nanoemulsion for cannabidiol ("CBD") beverages for one of its licensed clients. Lexaria's client expects to begin distribution of its line of CBD beverages in select US stores soon. Lexaria's emulsified DehydraTECH processing is an additional service it can now provide to qualifying clients wanting to formulate best in class ready-to-drink beverages containing CBD.

  • ACCESSWIRE

    Industry Solutions from Lexaria’s DehydraTECHTM Hemp and Cannabis Powders

    KELOWNA, BC / ACCESSWIRE / February 13, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability for financial savings by industry, solving key industry problems. Both CBD/hemp and cannabis consumers have recently become concerned about potency and safety of the oil extract products they are purchasing. Consumers have legitimate concerns about inventories of hemp or cannabis oil or plant matter being used to create products, and whether their potency is as advertised.

  • ACCESSWIRE

    Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

    KELOWNA, BC / ACCESSWIRE / January 22, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips' cannabis products, both in its current California market, and across all of the US. Cannadips Cannabis Tins are currently sold in California formulated with THC from cannabis. Cannadips recently executed a price adjustment to $14.99 and $24.99 respectively per tin MSRP plus tax in California in order to better align consumer expectations on price with product modality.

  • ACCESSWIRE

    Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

    KELOWNA, BC / ACCESSWIRE / January 14, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand. Cannadips CBD is America's leading and oldest oral pouch, similar to a Snus pouch, formulated with CBD from American hemp. Lexaria, already established as the leader in the CBD oral delivery, has been working with the Boldt Runners team behind the scenes to elevate the product experience.

  • ACCESSWIRE

    Lexaria Provides Strategic Update from CEO

    KELOWNA, BC / ACCESSWIRE / January 9, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the following strategic update. "Lexaria's brightest days lie in the future, not in the past," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. Lexaria achieved many things during 2019 - indeed, management feels that it achieved virtually all that it had set out to accomplish and it was its best year ever from an operational perspective.

  • ACCESSWIRE

    Lexaria’s Technology Now Works in Less Than 10 Minutes

    KELOWNA, BC / ACCESSWIRE / November 21, 2019 / Lexaria Bioscience Corp. (LXRP)(CSE LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has developed additional enhancements for its industry-leading DehydraTECHTM platform that delivers THC onset of action in human pilot testing in less than 10 minutes. In recent human subjective pilot tests, volunteers reported onset of THC action from edibles formulated with this latest DehydraTECH innovation in less than 10 minutes. This enhanced version is roughly twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations.

  • ACCESSWIRE

    Lexaria Bioscience Appoints Gregg Smith as Senior Advisor

    KELOWNA, BC / ACCESSWIRE / November 5, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to announce the appointment of Gregg Smith, Founder of Evolution VC Partners (www.evolutionvcp.com), as Senior Advisor. Evolution VC is a New York-based "culture tech" venture investment firm with more than 90 portfolio companies in many disruptive and emerging consumer-tech companies, including JUUL Labs, Pax Labs, Beyond Meat, Roman, Sweetgreen, Bird, New Wave Foods, Relativity Space and more. Prior to forming his investment company in 2007, Gregg spent 20 years on Wall Street as an investment banker focused on executing private equity placements with a strong focus on life sciences.

  • ACCESSWIRE

    Lexaria Applauds FDA Decision on Reduced Risk Tobacco Format

    KELOWNA, BC / ACCESSWIRE / October 24, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to report that, for the first time ever, the Food and Drug Administration (the "FDA") has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway, including product categories that could benefit from Lexaria's technology. The product format authorized by the FDA is in the tobacco pouch category, similar to a mini tea-bag that is held in the mouth from which the nicotine within is absorbed.

  • ACCESSWIRE

    Lexaria Bioscience Provides Update on R&D Program Progress under License Agreement with Altria

    KELOWNA, BC / ACCESSWIRE / October 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECHTM technology, underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) ("Altria") and Lexaria's majority owned subsidiary Lexaria Nicotine LLC ("Lexaria Nicotine"). Most of the investigation and work within this first phase of the project is either complete or significantly underway, with one remaining aspect ready to commence imminently.

  • ACCESSWIRE

    Peer Reviewed Clinical Journal Publishes Lexaria Bioscience's Human CBD Study Results

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / September 17, 2019 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECHTM powered TurboCBD™ capsules have been published in the peer reviewed medical journal, “Advances in Therapy”. Advances in Therapy focuses on clinical medicine and pharmaceutical research and has been published continually since 1984.

  • GlobeNewswire

    Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery

    While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be. Lexaria Bioscience Corp.’s DehydraTECH(TM) may be the most novel form of drug delivery discovered in decades. Fatty acids used in the technology mask the smell and taste of the drug and potentially greatly reduce stomach upset.

  • ACCESSWIRE

    Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

    KELOWNA, BC / ACCESSWIRE / August 27, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it has received a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 - “Stable ready-to-drink beverage compositions comprising lipophilic active agents”. Lexaria’s patent portfolio has increased to 16 awarded patents protecting its DehydraTECH™ drug delivery platform, with 8 granted in the USA and 8 granted in Australia. This new Australian patent, together with Australian Patent #2016367036 “Methods for formulating orally ingestible compositions comprising lipophilic active agents” announced on August 15, 2019, are the first patents granted in Lexaria’s second and third patent families which differ from the Company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof” under which 14 of Lexaria’s patents have been granted.

  • ACCESSWIRE

    Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

    KELOWNA, BC / ACCESSWIRE / August 22, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECHTM for fast, effective delivery. Long known as a technology innovator, Lexaria delivers patented processes within every serving of ChrgD+ to improve the consumer experience of hemp oil with CBD. ChrgD+ uses the highest quality multi-spectrum hemp oil ingredients and does NOT use CBD isolates that deprive consumers of the synergistic benefits of multi-spectrum oils.

  • More Companies Lining Up to Get Their Hands on Lexarias DehydraTECH Platform -- CFN Media
    Newsfile

    More Companies Lining Up to Get Their Hands on Lexarias DehydraTECH Platform -- CFN Media

    Seattle, Washington--(Newsfile Corp. - August 15, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology.When you've got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of ...

  • ACCESSWIRE

    Lexaria Bioscience Announces it has Received Four New Patents

    KELOWNA, BC / ACCESSWIRE / August 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted.

  • ACCESSWIRE

    Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

    KELOWNA, BC / ACCESSWIRE / August 14, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria's innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated. Mr. Quigley is a 20-year Consumer Packaged Goods veteran of managing complex regulatory environments including for novel and innovative nicotine products, with additional deep experience with operations and marketing.

  • ACCESSWIRE

    Lexaria Bioscience Receives Cannabis R&D License from Health Canada

    KELOWNA, BC / ACCESSWIRE / August 13, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed. Lexaria’s new cannabis R&D license is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose-built, is permitted at local and federal levels, fully outfitted with equipment required to produce DehydraTECHTM infusions as well as including two different methodologies by which the Company can create nano-sized molecules when deemed beneficial and is currently operational.

  • ACCESSWIRE

    Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

    KELOWNA, BC / ACCESSWIRE / August 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, announces the successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECHTM technology. A primary goal of the R&D Program was to determine whether Lexaria’s DehydraTECH technology causes the formation of a new molecular entity (“NME”) through its processing.

  • ACCESSWIRE

    Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

    KELOWNA, BC / ACCESSWIRE / August 2, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines. Integra partners with select underexposed and undervalued emerging growth company and leverages decades of market experience with a robust proprietary database to continuously maximize market visibility throughout their clients’ different development cycles. Integra is being engaged for an initial six-month contract and will receive US$12,500 per month and a total of 150,000 restricted common shares of the Company.

  • ACCESSWIRE

    Lexaria Bioscience Summarizes its Eleven Technology Licenses

    KELOWNA, BC / ACCESSWIRE / July 30, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, reports on its existing technology licensees that have signed definitive contracts to use Lexaria’s revolutionary DehydraTECHTM absorption technology within their existing and emerging brands. “The first half of 2019 delivered a period of unprecedented achievements for Lexaria,” said Chris Bunka, Chief Executive Officer. “We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous.